Comparing Innovation Spending: Ionis Pharmaceuticals, Inc. and PTC Therapeutics, Inc.

Biotech Giants' R&D Surge: Ionis vs. PTC

__timestampIonis Pharmaceuticals, Inc.PTC Therapeutics, Inc.
Wednesday, January 1, 201424175100079838000
Thursday, January 1, 2015322292000121816000
Friday, January 1, 2016344320000117633000
Sunday, January 1, 2017374644000117456000
Monday, January 1, 2018414604000171984000
Tuesday, January 1, 2019466000000257452000
Wednesday, January 1, 2020535000000477643000
Friday, January 1, 2021643000000540684000
Saturday, January 1, 2022833000000651496000
Sunday, January 1, 2023899625000666563000
Monday, January 1, 2024901530000
Loading chart...

In pursuit of knowledge

Innovation in Biotech: A Decade of R&D Investment

In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Ionis Pharmaceuticals, Inc. and PTC Therapeutics, Inc. have demonstrated significant dedication to advancing their scientific endeavors.

Ionis Pharmaceuticals, Inc.

From 2014 to 2023, Ionis Pharmaceuticals increased its R&D expenses by approximately 272%, reflecting a robust growth trajectory. By 2023, their investment in innovation reached nearly 900 million, underscoring their strategic focus on developing cutting-edge therapies.

PTC Therapeutics, Inc.

Similarly, PTC Therapeutics showcased a remarkable 735% increase in R&D spending over the same period. By 2023, their R&D expenses approached 667 million, highlighting their commitment to pioneering treatments.

This data not only illustrates the financial commitment of these companies but also their pivotal role in driving the future of biotechnology.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025